Cargando…

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

BACKGROUND: Revefenacin is a once-daily long-acting muscarinic antagonist (LAMA) in clinical development for the treatment of patients with chronic obstructive pulmonary disease (COPD). In a dose-ranging study, nebulized once-daily revefenacin had a long duration of action in patients after 7 days’...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pudi, Krishna K., Barnes, Chris N., Moran, Edmund J., Haumann, Brett, Kerwin, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667509/ https://www.ncbi.nlm.nih.gov/pubmed/29096627 http://dx.doi.org/10.1186/s12931-017-0647-1

Ejemplares similares

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
por: Donohue, James F., et al.
Publicado: (2020)

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease
por: Donohue, James, et al.
Publicado: (2019)

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)
por: Donohue, James F., et al.
Publicado: (2019)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

The Role of Revefenacin in Chronic Obstructive Pulmonary Disease
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease
por: Hvisdas, Christopher
Publicado: (2021)

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
por: Sethi, Sanjay, et al.
Publicado: (2020)

Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease
por: Lo, Arthur, et al.
Publicado: (2020)

Revefenacin: First Global Approval
por: Heo, Young-A
Publicado: (2018)

Correction to: Revefenacin: First Global Approval
por: Heo, Young-A
Publicado: (2019)

Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function
por: Borin, Marie T, et al.
Publicado: (2019)

The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review
por: Zhang, Jiaxing, et al.
Publicado: (2021)

Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies
por: Kerwin, Edward M, et al.
Publicado: (2020)

Nebulized Budesonide vs. Placebo in Adults with Asthma Attack; a Double Blind Randomized Placebo-Controlled Clinical Trial
por: Sheikh-Motahar-Vahedi, Hojat, et al.
Publicado: (2018)

In Vitro Evaluation of a Vibrating-Mesh Nebulizer Repeatedly Use over 28 Days
por: Lin, Hui-Ling, et al.
Publicado: (2020)

Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
por: Borin, Marie T., et al.
Publicado: (2019)

Nebulized lignocaine for topical anaesthesia in no-sedation bronchoscopy (NEBULA): A randomized, double blind, placebo-controlled trial
por: Madan, Karan, et al.
Publicado: (2019)

Is nebulized saline a placebo in COPD?
por: Khan, Shahina Y, et al.
Publicado: (2004)

Pharmacological properties of revefenacin (TD‐4208), a novel, nebulized long‐acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues
por: Hegde, Sharath S., et al.
Publicado: (2018)

Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease
por: Leaker, Brian R, et al.
Publicado: (2015)

Safety and efficacy of an herbal formulation in patients with renal calculi - A 28 week, randomized, double-blind, placebo-controlled, parallel group study
por: Patankar, Suresh B., et al.
Publicado: (2020)

Effect of nebulized budesonide in preventing postextubation complications in critically patients: A prospective, randomized, double-blind, placebo-controlled study
por: Abbasi, Saeed, et al.
Publicado: (2014)

Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial
por: Emara, Moataz Maher, et al.
Publicado: (2022)

The Effect of Aclidinium on Symptoms Including Cough in Chronic Obstructive Pulmonary Disease: A Phase 4, Double-Blind, Placebo-controlled, Parallel-Group Study
por: Smith, Jaclyn A., et al.
Publicado: (2019)

In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution
por: Pham, Stephen, et al.
Publicado: (2018)

Effect of Nebulized BromAc on Rheology of Artificial Sputum: Relevance to Muco-Obstructive Respiratory Diseases
por: Pillai, Krishna, et al.
Publicado: (2023)

Randomized, Double-Blind, Placebo-Controlled Parallel Clinical Trial Assessing the Effect of Fructooligosaccharides in Infants with Constipation
por: Souza, Daniela da Silva, et al.
Publicado: (2018)

Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
por: Caponnetto, Pasquale, et al.
Publicado: (2023)

Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease
por: Santus, Pierachille, et al.
Publicado: (2017)

Nebulized hypertonic saline 3% for 1 versus 3 days in hospitalized bronchiolitis: a blinded non-inferiority randomized controlled trial
por: Beal, Gaëlle, et al.
Publicado: (2019)

Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide
por: McCaffrey, Nikki, et al.
Publicado: (2020)

A parallel, randomized, double-blind, placebo-controlled study to investigate the effect of SagaPro on nocturia in men
por: Sigurdsson, Steinthor, et al.
Publicado: (2013)

A randomized, double-blind, placebo controlled, parallel group, efficacy study of alpha BRAIN(® )administered orally
por: Solomon, Todd M, et al.
Publicado: (2015)

The effect of vitamin D on COPD exacerbation: a double blind randomized placebo-controlled parallel clinical trial
por: Sanjari, Mojgan, et al.
Publicado: (2016)

Pregabalin to improve postoperative recovery in bariatric surgery: a parallel, randomized, double-blinded, placebo-controlled study
por: Martins, Marcelo J, et al.
Publicado: (2018)

Evaluation effects of nebulized gentamicin in exacerbation of chronic obstructive lung disease
por: Soltaninejad, Forogh, et al.
Publicado: (2016)

Methylphenidate for Mild Cognitive Impairment: An Exploratory 3-Day, Randomized, Double-Blind, Placebo-Controlled Trial
por: Press, Yan, et al.
Publicado: (2021)

A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA
por: Panda, Sanjib kumar, et al.
Publicado: (2018)

Nebulized heparin and salbutamol versus salbutamol alone in acute exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation: a double-blind randomized controlled trial
por: Ashoor, Tarek Mohamed, et al.
Publicado: (2020)

A randomised, double-blind, placebo-controlled parallel trial of closed-loop infraslow brain training in food addiction
por: Leong, Sook Ling, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o254tj4egp700rjh22tk5557h1